Allogene Therapeutics's three largest insider shareholders as of April 17, 2026 are David D Chang (President And Ceo, 5.15Mn shares), Geoffrey M. Parker (Chief Financial Officer, 1.25Mn shares), Eric Thomas Schmidt (Chief Financial Officer, 862.44K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| David D Chang | President And Ceo | 5,150,599 | 0 | 18 Mar, 2026 |
| Geoffrey M. Parker | Chief Financial Officer | 1,252,795 | 0 | 04 Feb, 2026 |
| Eric Thomas Schmidt | Chief Financial Officer | 862,439 | 0 | 24 Mar, 2023 |
| Alison Moore | Chief Technical Officer | 672,731 | 0 | 24 Mar, 2023 |
| Zachary Roberts | Evp Of Rd | 581,166 | 0 | 04 Feb, 2026 |
| Earl Martin Douglas | Svp, General Counsel | 564,948 | 0 | 04 Feb, 2026 |
| Veer Bhavnagri | General Counsel | 556,049 | 0 | 16 Mar, 2023 |
| Joshua A Kazam | - | 350,763 | 0 | 22 Dec, 2025 |
| Owen N. Witte | - | 292,832 | 0 | 15 Jun, 2023 |
| Timothy L. Moore | Chief Technical Officer | 250,713 | 0 | 05 Feb, 2025 |
| Benjamin Machinas Beneski | Svp, Chief Technical Officer | 195,338 | 0 | 02 Apr, 2026 |
| Lillian Smith | Vp, Corporate Counsel | 140,390 | 0 | 05 Apr, 2023 |
| Annie Yoshiyama | Svp, Finance | 130,322 | 0 | 04 Feb, 2026 |
| Deborah M. Messemer | - | 107,431 | 0 | 12 Jun, 2025 |
| Yinlin Jack Chen | Svp, Finance | 88,881 | 0 | 14 Aug, 2023 |
| Stephen Mayo | - | 25,328 | 0 | 09 Aug, 2023 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 31 Mar, 2026 | Benjamin Machinas Beneski | Common Stock | D | 2,867 | $2.50 | 195,338 | D | S |
| 16 Mar, 2026 | Benjamin Machinas Beneski | Common Stock | D | 4,835 | $2.47 | 198,205 | D | S |
| 16 Mar, 2026 | David D Chang | Common Stock | D | 47,763 | $2.47 | 5,150,599 | D | S |
| 02 Mar, 2026 | Benjamin Machinas Beneski | Common Stock | D | 7,132 | $2.60 | 203,040 | D | S |
| 02 Feb, 2026 | Earl Martin Douglas | Common Stock | D | 22,900 | $1.76 | 564,948 | D | S |
| 02 Feb, 2026 | Zachary Roberts | Common Stock | D | 35,700 | $1.77 | 581,166 | D | S |
| 02 Feb, 2026 | Annie Yoshiyama | Common Stock | D | 4,167 | $1.72 | 130,322 | D | S |
| 02 Feb, 2026 | Benjamin Machinas Beneski | Common Stock | D | 7,549 | $1.73 | 210,172 | D | S |
| 02 Feb, 2026 | Geoffrey M. Parker | Common Stock | D | 24,001 | $1.76 | 1,252,795 | D | S |
| 02 Feb, 2026 | David D Chang | Common Stock | D | 95,269 | $1.80 | 5,185,862 | D | S |
| 02 Feb, 2026 | Annie Yoshiyama | Stock Option (Right to buy) | A | 179,691 | $0.00 | 179,691 | D | A |
| 02 Feb, 2026 | Benjamin Machinas Beneski | Stock Option (Right to buy) | A | 373,757 | $0.00 | 373,757 | D | A |
| 02 Feb, 2026 | Earl Martin Douglas | Stock Option (Right to buy) | A | 539,072 | $0.00 | 539,072 | D | A |
| 02 Feb, 2026 | Zachary Roberts | Stock Option (Right to buy) | A | 718,763 | $0.00 | 718,763 | D | A |
| 02 Feb, 2026 | Geoffrey M. Parker | Stock Option (Right to buy) | A | 539,072 | $0.00 | 539,072 | D | A |
| 02 Feb, 2026 | Annie Yoshiyama | Restricted Stock Unit | A | 50,827 | $0.00 | 50,827 | D | A |
| 02 Feb, 2026 | Zachary Roberts | Restricted Stock Unit | A | 203,307 | $0.00 | 203,307 | D | A |
| 02 Feb, 2026 | Geoffrey M. Parker | Restricted Stock Unit | A | 152,480 | $0.00 | 152,480 | D | A |
| 02 Feb, 2026 | Earl Martin Douglas | Restricted Stock Unit | A | 152,480 | $0.00 | 152,480 | D | A |
| 02 Feb, 2026 | Benjamin Machinas Beneski | Restricted Stock Unit | A | 105,720 | $0.00 | 105,720 | D | A |